Tarsus Pharmaceuticals, Inc. TARS
TARS among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
TARS and 9 peers, year by year
The 9 Health care companies closest to TARS in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Gross margin | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals, Inc. | FY2025 | $451.4M | +147% | - | −15.7% | −14.7% | −4.9% | −19.3% | 0.21 |
| GKOS GLAUKOS Corp | FY2025 | $507.4M | +32.3% | 55.7% | −39.3% | −37.0% | −4.4% | −28.6% | - |
| MIRM Mirum Pharmaceuticals, Inc. | FY2025 | $521.3M | +54.7% | - | −4.2% | −4.5% | 10.5% | −7.4% | - |
| UFPT UFP Technologies Inc | FY2025 | $602.8M | +19.5% | 28.3% | 15.3% | 11.3% | - | 16.1% | 0.32 |
| TMDX TransMedics Group, Inc. | FY2025 | $605.5M | +37.1% | 59.9% | 17.9% | 31.4% | 22.1% | 40.2% | - |
| RARE Ultragenyx Pharmaceutical Inc. | FY2025 | $673.0M | +20.2% | - | −79.5% | −85.4% | −70.1% | n/m | - |
| VCYT Veracyte, Inc. | FY2025 | $517.1M | +16.0% | 70.1% | 11.2% | 12.8% | 24.5% | 5.1% | - |
| RGEN Repligen Corp | FY2025 | $738.3M | +16.4% | - | 7.5% | 6.6% | 12.7% | 2.3% | 0.26 |
| PTGX Protagonist Therapeutics, Inc | FY2025 | $46.0M | −89.4% | - | −343.6% | −282.8% | 121.9% | −21.2% | - |
| ADMA Adma Biologics, Inc. | FY2025 | $510.2M | +19.6% | 57.4% | 37.5% | 28.8% | 5.5% | 30.8% | 0.15 |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2018 to FY2025 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2018 to FY2025
Revenue as reported in the 10-K.
| Company | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| TARS Dec | - | - | $0 | $57.0M | $25.8M | $17.4M | $183.0M | $451.4M |
| GKOS Dec | $181.3M | $237.0M | $225.0M | $294.0M | $282.9M | $314.7M | $383.5M | $507.4M |
| MIRM Dec | - | - | $0 | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M |
| UFPT Dec | $190.5M | $198.4M | $179.4M | $206.3M | $353.8M | $400.1M | $504.4M | $602.8M |
| TMDX Dec | $14.7M | $25.8M | $28.4M | $31.4M | $93.5M | $241.6M | $441.5M | $605.5M |
| RARE Dec | $51.5M | $103.7M | $271.0M | $351.4M | $363.3M | $434.0M | $560.0M | $673.0M |
| VCYT Dec | $92.0M | $120.4M | $117.5M | $219.5M | $296.5M | $361.1M | $445.8M | $517.1M |
| RGEN Dec | $194.0M | $270.2M | $366.3M | $670.5M | $801.5M | $632.4M | $634.4M | $738.3M |
| PTGX Dec | $30.9M | $231K | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | $46.0M |
| ADMA Dec | $17.0M | $29.3M | $42.2M | $80.9M | $154.1M | $258.2M | $426.5M | $510.2M |
| Peer median | $71.8M | $112.0M | $117.5M | $206.3M | $282.9M | $314.7M | $441.5M | $521.3M |
Sales growth, FY2018 to FY2025
Revenue against the fiscal year before.
| Company | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| TARS Dec | - | - | - | - | −54.7% | −32.4% | +949% | +147% |
| GKOS Dec | +13.8% | +30.7% | −5.1% | +30.7% | −3.8% | +11.3% | +21.9% | +32.3% |
| MIRM Dec | - | - | - | - | +303% | +142% | +80.8% | +54.7% |
| UFPT Dec | +28.8% | +4.2% | −9.6% | +15.0% | +71.5% | +13.1% | +26.1% | +19.5% |
| TMDX Dec | - | +76.3% | +9.7% | +18.0% | +209% | +159% | +82.7% | +37.1% |
| RARE Dec | n/m | +101% | +161% | +29.7% | +3.4% | +19.5% | +29.0% | +20.2% |
| VCYT Dec | +27.9% | +30.8% | −2.4% | +86.8% | +35.1% | +21.8% | +23.5% | +16.0% |
| RGEN Dec | +37.4% | +39.3% | +35.5% | +83.1% | +19.5% | −21.1% | +0.3% | +16.4% |
| PTGX Dec | +54.1% | −99.3% | n/m | −4.4% | −2.8% | +126% | +624% | −89.4% |
| ADMA Dec | −25.4% | +72.8% | +43.9% | +91.7% | +90.4% | +67.6% | +65.2% | +19.6% |
| Peer median | +28.3% | +35.1% | +9.7% | +30.2% | +35.1% | +21.8% | +29.0% | +19.6% |
Gross margin, FY2018 to FY2025
Gross profit / revenue.
| Company | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| TARS Dec | - | - | - | - | - | - | - | - |
| GKOS Dec | 86.2% | 83.7% | 59.2% | 77.3% | 75.6% | 76.0% | 75.5% | 55.7% |
| MIRM Dec | - | - | - | - | - | - | - | - |
| UFPT Dec | 25.4% | 27.2% | 24.9% | 24.8% | 25.5% | 28.1% | 29.1% | 28.3% |
| TMDX Dec | 39.1% | 53.6% | 58.7% | 67.4% | 69.8% | 63.8% | 59.4% | 59.9% |
| RARE Dec | - | - | - | - | - | - | - | - |
| VCYT Dec | - | - | - | - | 59.2% | 63.6% | 66.9% | 70.1% |
| RGEN Dec | - | - | - | - | - | - | - | - |
| PTGX Dec | - | - | - | - | - | - | - | - |
| ADMA Dec | −148.4% | - | −45.2% | 1.4% | 22.9% | 34.4% | 51.5% | 57.4% |
| Peer median | 32.2% | 53.6% | 41.8% | 46.1% | 59.2% | 63.6% | 59.4% | 57.4% |
Operating margin, FY2018 to FY2025
Operating income / revenue.
| Company | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| TARS Dec | - | - | - | −21.3% | −242.9% | −820.5% | −65.9% | −15.7% |
| GKOS Dec | −7.2% | −21.2% | −54.9% | −11.2% | −29.1% | −40.9% | −31.9% | −39.3% |
| MIRM Dec | - | - | - | −906.1% | −170.3% | −58.6% | −26.0% | −4.2% |
| UFPT Dec | 10.3% | 12.5% | 9.3% | 10.3% | 15.7% | 14.4% | 16.0% | 15.3% |
| TMDX Dec | −138.1% | −114.5% | −93.0% | −125.6% | −33.6% | −11.9% | 8.5% | 17.9% |
| RARE Dec | −721.2% | −409.0% | −121.8% | −108.6% | −178.6% | −131.1% | −95.7% | −79.5% |
| VCYT Dec | −24.2% | −12.6% | −30.1% | −37.3% | −13.9% | −23.8% | 3.6% | 11.2% |
| RGEN Dec | 13.4% | 13.4% | 19.1% | 24.9% | 28.0% | 7.5% | −5.5% | 7.5% |
| PTGX Dec | −136.7% | n/m | −225.4% | −460.0% | −494.2% | −156.1% | 58.2% | −343.6% |
| ADMA Dec | −354.9% | −141.1% | −153.8% | −72.1% | −25.5% | 8.4% | 32.6% | 37.5% |
| Peer median | −80.4% | −21.2% | −74.0% | −72.1% | −29.1% | −23.8% | 3.6% | 7.5% |
Net margin, FY2018 to FY2025
Net income / revenue.
| Company | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| TARS Dec | - | - | - | −24.2% | −240.5% | −778.9% | −63.2% | −14.7% |
| GKOS Dec | −7.1% | 6.5% | −53.5% | −16.9% | −35.1% | −42.8% | −38.2% | −37.0% |
| MIRM Dec | - | - | - | −438.9% | −176.0% | −87.7% | −26.1% | −4.5% |
| UFPT Dec | 7.5% | 10.0% | 7.5% | 7.7% | 11.8% | 11.2% | 11.7% | 11.3% |
| TMDX Dec | −162.1% | −129.8% | −101.4% | −140.9% | −38.8% | −10.4% | 8.0% | 31.4% |
| RARE Dec | −383.7% | −388.3% | −68.8% | −129.2% | −194.7% | −139.9% | −101.6% | −85.4% |
| VCYT Dec | −25.0% | −10.5% | −29.7% | −34.4% | −12.3% | −20.6% | 5.4% | 12.8% |
| RGEN Dec | 8.6% | 7.9% | 16.4% | 19.1% | 23.2% | 5.6% | −4.0% | 6.6% |
| PTGX Dec | −125.9% | n/m | −231.1% | −458.9% | −479.3% | −131.6% | 63.3% | −282.8% |
| ADMA Dec | −387.1% | −164.5% | −179.4% | −88.5% | −42.8% | −10.9% | 46.4% | 28.8% |
| Peer median | −75.4% | −10.5% | −61.2% | −88.5% | −38.8% | −20.6% | 5.4% | 6.6% |
Free cash flow, FY2018 to FY2025
Cash from operations minus capital spending.
| Company | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| TARS Dec | - | −$3.8M | −$21.6M | $3.2M | −$49.5M | −$119.0M | −$84.6M | −$22.3M |
| GKOS Dec | $8.5M | −$5.1M | −$29.9M | −$23.1M | −$63.3M | −$78.0M | −$67.6M | −$22.5M |
| MIRM Dec | - | −$39.6M | −$89.3M | −$132.8M | −$120.4M | −$71.1M | $9.3M | $54.9M |
| UFPT Dec | $15.9M | $25.5M | $20.7M | $8.9M | $4.0M | $30.8M | $56.9M | - |
| TMDX Dec | −$26.4M | −$32.5M | −$30.7M | −$32.4M | −$57.7M | −$164.9M | −$80.9M | $133.6M |
| RARE Dec | −$294.6M | −$370.2M | −$176.1M | −$411.8M | −$496.6M | −$519.0M | −$421.0M | −$472.0M |
| VCYT Dec | −$15.4M | −$6.0M | −$12.5M | −$37.0M | −$1.0M | $34.3M | $63.8M | $126.6M |
| RGEN Dec | $22.1M | $48.7M | $40.2M | $51.9M | $87.2M | $77.7M | $149.7M | $93.9M |
| PTGX Dec | −$50.4M | −$42.5M | −$73.0M | −$109.0M | −$108.9M | −$70.8M | $182.8M | $56.1M |
| ADMA Dec | −$64.8M | −$80.0M | −$114.7M | −$125.9M | −$73.4M | $4.0M | $110.4M | $27.8M |
| Peer median | −$20.9M | −$32.5M | −$30.7M | −$37.0M | −$63.3M | −$70.8M | $56.9M | $55.5M |
FCF margin, FY2018 to FY2025
Free cash flow / revenue.
| Company | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| TARS Dec | - | - | - | 5.5% | −191.9% | −682.0% | −46.2% | −4.9% |
| GKOS Dec | 4.7% | −2.1% | −13.3% | −7.8% | −22.4% | −24.8% | −17.6% | −4.4% |
| MIRM Dec | - | - | - | −693.8% | −156.3% | −38.1% | 2.8% | 10.5% |
| UFPT Dec | 8.3% | 12.8% | 11.5% | 4.3% | 1.1% | 7.7% | 11.3% | - |
| TMDX Dec | −180.1% | −125.6% | −108.3% | −103.2% | −61.8% | −68.2% | −18.3% | 22.1% |
| RARE Dec | −572.2% | −357.0% | −65.0% | −117.2% | −136.7% | −119.6% | −75.2% | −70.1% |
| VCYT Dec | −16.7% | −5.0% | −10.7% | −16.9% | −0.3% | 9.5% | 14.3% | 24.5% |
| RGEN Dec | 11.4% | 18.0% | 11.0% | 7.7% | 10.9% | 12.3% | 23.6% | 12.7% |
| PTGX Dec | −163.1% | n/m | −254.8% | −398.3% | −409.8% | −118.1% | 42.1% | 121.9% |
| ADMA Dec | −381.4% | −272.6% | −271.7% | −155.5% | −47.6% | 1.6% | 25.9% | 5.5% |
| Peer median | −89.9% | −5.0% | −39.1% | −103.2% | −47.6% | −24.8% | 11.3% | 11.6% |
Return on equity, FY2018 to FY2025
Net income / shareholders' equity at the year end.
| Company | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| TARS Dec | n/m | n/m | −16.2% | −8.3% | −32.2% | −69.0% | −51.5% | −19.3% |
| GKOS Dec | −7.4% | 2.3% | −18.0% | −8.4% | −18.7% | −29.2% | −19.1% | −28.6% |
| MIRM Dec | - | −40.3% | −60.0% | −69.9% | −95.5% | −65.7% | −39.0% | −7.4% |
| UFPT Dec | 10.2% | 12.2% | 7.6% | 8.2% | 17.6% | 15.7% | 17.2% | 16.1% |
| TMDX Dec | n/m | −61.4% | −27.7% | −65.2% | −19.3% | −18.2% | 15.5% | 40.2% |
| RARE Dec | −32.5% | −61.6% | −16.2% | −49.2% | n/m | n/m | n/m | n/m |
| VCYT Dec | −28.8% | −5.3% | −8.3% | −6.9% | −3.4% | −7.1% | 2.1% | 5.1% |
| RGEN Dec | 2.7% | 2.0% | 3.9% | 7.3% | 9.7% | 1.8% | −1.3% | 2.3% |
| PTGX Dec | −34.6% | −96.5% | −23.7% | −41.8% | −59.1% | −23.5% | 40.8% | −21.2% |
| ADMA Dec | n/m | −184.3% | −85.8% | −50.8% | −43.4% | −20.9% | 56.6% | 30.8% |
| Peer median | −18.1% | −40.3% | −18.0% | −41.8% | −19.0% | −19.6% | 8.8% | 3.7% |
Debt / equity, FY2018 to FY2025
Total debt / shareholders' equity at the year end.
| Company | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| TARS Dec | - | - | - | 0.00 | 0.10 | 0.15 | 0.32 | 0.21 |
| GKOS Dec | - | - | - | - | - | - | - | - |
| MIRM Dec | - | - | - | - | - | - | - | - |
| UFPT Dec | 0.18 | - | 0.00 | 0.39 | 0.23 | 0.11 | 0.55 | 0.32 |
| TMDX Dec | n/m | 0.62 | 0.33 | 0.52 | 0.31 | - | - | - |
| RARE Dec | - | - | - | - | - | - | - | - |
| VCYT Dec | 0.32 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| RGEN Dec | - | - | - | - | - | - | 0.27 | 0.26 |
| PTGX Dec | - | 0.12 | - | - | - | - | - | - |
| ADMA Dec | 0.14 | 0.00 | 1.05 | - | - | - | 0.21 | 0.15 |
| Peer median | 0.18 | 0.06 | 0.17 | 0.39 | - | - | 0.27 | 0.26 |
EPS (diluted), FY2018 to FY2025
Diluted earnings per share, on today's share count after splits.
| Company | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| TARS Dec | - | −$1.98 | −$4.32 | −$0.67 | −$2.52 | −$4.62 | −$3.07 | −$1.59 |
| GKOS Dec | −$0.37 | $0.37 | −$2.70 | −$1.07 | −$2.09 | −$2.78 | −$2.77 | −$3.28 |
| MIRM Dec | - | −$4.58 | −$4.09 | −$2.77 | −$4.02 | −$4.00 | −$1.85 | −$0.47 |
| UFPT Dec | $1.93 | $2.63 | $1.77 | $2.09 | $5.45 | $5.83 | $7.58 | $8.75 |
| TMDX Dec | −$17.48 | −$2.36 | −$1.16 | −$1.60 | −$1.23 | −$0.77 | $1.01 | $4.87 |
| RARE Dec | −$3.97 | −$7.12 | −$3.07 | −$6.70 | −$10.12 | −$8.25 | −$6.29 | −$5.83 |
| VCYT Dec | −$0.62 | −$0.27 | −$0.66 | −$1.11 | −$0.51 | −$1.02 | $0.31 | $0.82 |
| RGEN Dec | $0.37 | $0.44 | $1.11 | $2.24 | $3.24 | $0.63 | −$0.46 | $0.86 |
| PTGX Dec | −$1.74 | −$2.98 | −$1.92 | −$2.71 | −$2.60 | −$1.39 | $4.23 | −$2.05 |
| ADMA Dec | −$1.45 | −$0.89 | −$0.88 | −$0.51 | −$0.33 | −$0.13 | $0.81 | $0.60 |
| Peer median | −$1.03 | −$0.89 | −$1.16 | −$1.11 | −$1.23 | −$1.02 | $0.31 | $0.60 |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out TARS and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: TARS's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TARS/export.csv") into a cell.